Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211966 | 1.00 | ACE2 (0.51) | ACE2ALDH1A1HPGDGRM1MEN1 | |
| SCHEMBL26458007 | 0.86 | CYP2A6 (0.40) | ACE2ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL17014697 | 0.86 | ALDH1A1 (0.48) | ACE2ALDH1A1HPGDGRM1MEN1 | |
| SCHEMBL7978961 | 0.85 | GLRA1 (0.38) | ACE2ALDH1A1HPGD | |
| SCHEMBL9636754 | 0.83 | ALDH1A1 (0.43) | ACE2ALDH1A1HPGDGRM1MEN1 | |
| SCHEMBL27974667 | 0.83 | ACE2 (0.51) | ACE2GRM1MEN1CYP1A2KMT2A | |
| SCHEMBL29974769 | 0.83 | ALDH1A1 (0.44) | ACE2ALDH1A1HPGDGRM1MEN1 | |
| SCHEMBL22747128 | 0.83 | ALDH1A1 (0.44) | ACE2ALDH1A1HPGDGRM1MEN1 | |
| SCHEMBL16954103 | 0.82 | SLC22A12 (0.34) | ACE2ALDH1A1HPGD | |
| SCHEMBL3902854 | 0.82 | CA1 (0.45) | ALDH1A1HPGDMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697485-B | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| EP-4157447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-04-05 | — | — | EP | disclosed |
| CN-115697485-A | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-109661391-B | S1P1 agonist and application thereof | 南京明德新药研发有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-109071469-B | Tricyclic compound and application thereof | 南京明德新药研发有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-11192886-B2 | S1P1 agonist and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2021-12-07 | — | — | US | disclosed |
| WO-2021239643-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-12-02 | — | — | WO | disclosed |
| US-20210300908-A1 | S1P1 AGONIST AND APPLICATION THEREOF | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2021-09-30 | — | — | US | disclosed |
| EP-3492465-B1 | S1P1 AGONIST AND APPLICATION THEREOF | SHIJIAZHUANG SAGACITY NEW DRUG DEV CO LTD (CN) | 2021-03-24 | — | — | EP | disclosed |
| US-6245778-B1 | 1,6-naphthyridine anti-convulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-06-12 | — | — | US | disclosed |
| EP-1102769-A2 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2001-05-30 | — | — | EP | disclosed |
| WO-2001002366-A2 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS INTICONVULSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-01-11 | — | — | WO | disclosed |
| EP-0986559-A1 | 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000008020-A2 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-17 | — | — | WO | disclosed |
| EP-0971897-A1 | ANTI-CONVULSANT ISOQUINOLYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2000-01-19 | — | — | EP | disclosed |
| EP-0968190-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998054184-A1 | 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998041507-A1 | ANTI-CONVULSANT ISOQUINOLYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1998-09-24 | — | — | WO | disclosed |
| WO-1998041508-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192886-B2 | S1P1 agonist and application thereof | S1PR1, S1PR2, S1PR3 | ACE2 2202/4885ALDH1A1 2418/4885HPGD 3791/4885 |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | DDR2, DDR1, DDRGK1 | ACE2 1370/4885ALDH1A1 2102/4885HPGD 3240/4885 |
| US-20210300908-A1 | S1P1 AGONIST AND APPLICATION THEREOF | S1PR1, S1PR2, S1PR3 | ACE2 2202/4885ALDH1A1 2418/4885HPGD 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.